The science
What the research on psychedelics shows.
I read these studies so you can see what they found. Every claim names its source, and I state the limits in plain English.

What was measured
Three places the evidence comes from.
Psilocybin research draws on three kinds of evidence. They answer different questions, and only the first two involve people.

During the experience.
Human fMRI studies report reduced default mode network integration while psilocybin is active. The network is linked to self-referential thought. In 30 healthy volunteers, blood flow dropped and coupling weakened between the medial prefrontal and posterior cingulate cortex (Carhart-Harris et al., PNAS 2012).
Weeks later, in patients.
In patients with depression, fMRI measured increased global brain integration about three weeks after psilocybin therapy (Daws et al., Nature Medicine 2022). Whether this explains any benefit is not yet known.
In rodents.
In mice, one psilocybin dose raised dendritic spine density and size by about 10% within 24 hours, and the change persisted at one month (Shao et al., Neuron 2021). In cultured rodent neurons and rodent cortex, psychedelics increased neurite growth, dendritic spines and synapse number (Ly et al., Cell Reports 2018). In mice, a social-reward-learning critical period stayed open at two weeks and had closed by three (Nardou et al., Nature 2023).
Human structural plasticity has not been measured directly, and no human plasticity window has been established. These are indirect markers from small studies, so the practical reading is modest: the evidence does not show that the drug alone produces lasting change, and no trial has tested whether integration support lengthens benefits.
How we cite
Each study on this page is named with its authors, year and journal. Click any citation to read the original paper. If a study is paywalled, the DOI is the permanent identifier; it will resolve at any institutional library you have access to.
We do not paraphrase results to make them friendlier. Where a figure comes from a company press release or a trial registry rather than a peer-reviewed paper, we label it as sponsor-reported. Where a mechanism comes from animal work, we say so.
The research
Three trials you can read yourself.
Three flagship trials, each with a public DOI.
Imperial College London
Centre for Psychedelic Research
“Trial of Psilocybin versus Escitalopram for Depression”
Carhart-Harris RL, Giribaldi B, Watts R, et al.
New England Journal of Medicine, 2021Johns Hopkins Medicine
Center for Psychedelic & Consciousness Research
“Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer”
Griffiths RR, Johnson MW, Carducci MA, et al.
Journal of Psychopharmacology, 2016MAPS Public Benefit Corporation
Multidisciplinary Association for Psychedelic Studies
“MDMA-assisted therapy for severe PTSD: a randomised, double-blind, placebo-controlled phase 3 study”
Mitchell JM, Bogenschutz M, Lilienstein A, et al.
Nature Medicine, 2021
Published research
What the major trials found
−3.6 and −3.8
COMPASS phase 3, sponsor-reported
MADRS point difference at week 6 in the two phase 3 trials of psilocybin for treatment-resistant depression. Modest absolute differences; not yet fully peer-reviewed.
−12.0 vs −5.4
Dose finding
MADRS points at week 3 for 25 mg vs 1 mg psilocybin in treatment-resistant depression (n=233). The 10 mg dose did not differ significantly from 1 mg.
p = 0.17
Psilocybin vs escitalopram
No significant difference on the primary outcome (n=59) between two psilocybin doses and six weeks of escitalopram. Several secondary outcomes favored psilocybin but were not corrected for multiple comparisons.
~4%
Serious adverse events
Share of trial participants with neuropsychiatric disorders who had a serious adverse event, in a systematic review of 214 studies (114 with analyzable data, 3,504 participants). None were reported in healthy participants.
These are research findings from controlled settings; they do not describe outcomes at a retreat. Full citations: see the published studies above.
What's in trial
The active trials.
A snapshot of the late-stage trials moving toward regulatory review, last reviewed October 2026. Sourced from ClinicalTrials.gov and sponsor disclosures, so company figures are sponsor-reported rather than independently peer-reviewed. Verify current status before citing.
COMPASS Pathways
COMP360 (synthetic psilocybin, 25 mg)
Treatment-resistant depression
Phase 3 reported
COMP005 complete; COMP006 active, not recruiting
Sponsor-reported: both trials met their primary endpoints, with modest week-6 MADRS differences (see the research figures above). Rolling NDA under way, final submission expected Q4 2026. Not FDA-approved.
Resilient Pharmaceuticals (formerly Lykos Therapeutics)
MDMA-assisted therapy
Severe PTSD
Phase 3 complete
Not approved
FDA issued a Complete Response Letter on 2024-08-09. A resubmission was reported in August 2026 by MAPS and trade press; FDA has not announced acceptance.
Usona Institute
Psilocybin
Major depressive disorder
Phase 3
Enrollment complete
NCT06308653: randomized, double-blind; results not yet public. Breakthrough Therapy designation (2019).
Go deeper, one page at a time.
Pharmacology
Research IndexEach study with its DOI, who was studied, and what the trial did not show. Johns Hopkins, Imperial College, and the COMPASS and Usona phase 3 programs.
Neuroscience
The Default Mode NetworkA brain network linked to self-referential thought, and what imaging studies report after psilocybin.
Neuroscience
NeuroplasticityWhat was measured, in whom, and for how long: preclinical findings in mice and what human imaging has shown.
Pharmacology
MicrodosingWhat placebo-controlled, self-blinding and survey studies report, and the open safety questions. Education only.
Pharmacology
Ayahuasca and DMTHow DMT becomes orally active, and what the small clinical literature on ayahuasca has found.
Psychology
Trauma-Informed CareWhat trauma-informed means, the Window of Tolerance, what the trials found, and why screening comes first.
Framework
Our MethodHow we work: our practice, not a research finding. Read it on its own terms.
Frequently asked
The questions people search for.
Is psychedelic therapy FDA approved?
No. As of October 2026, no psilocybin or MDMA product is FDA-approved. FDA granted Breakthrough Therapy designation to COMPASS Pathways' psilocybin (COMP360) for treatment-resistant depression in 2018 and to Usona Institute's psilocybin for major depressive disorder in 2019; that is a development-pathway status, not approval. COMPASS has reported positive phase 3 results (sponsor-reported) and has begun a rolling submission to FDA. For MDMA-assisted therapy in PTSD trials, FDA issued a Complete Response Letter on 2024-08-09, and it is not approved. Esketamine (Spravato), a ketamine-related medicine, is FDA-approved for treatment-resistant depression.
How do psychedelics work in the brain?
Classical psychedelics such as psilocybin, LSD and DMT act mainly at the serotonin 2A (5-HT2A) receptor, which is dense on cortical pyramidal neurons (reviewed in Carhart-Harris and Friston, Pharmacological Reviews 2019). Human fMRI studies report reduced default-mode network integrity during the acute effects and increased global integration weeks later in patients (Carhart-Harris et al., PNAS 2012; Daws et al., Nature Medicine 2022). In rodent neurons and cortex, psychedelics increased neurite growth and dendritic spines via 5-HT2A, TrkB and mTOR signaling (Ly et al., Cell Reports 2018). A BDNF surge after psilocybin has not been shown in humans.
What did MDMA trials for PTSD find?
In the Mitchell trial of MDMA-assisted therapy for severe PTSD (n=90), 28 of 42 (67%) in the MDMA group no longer met PTSD criteria at 18 weeks vs 12 of 37 (32%) on placebo (Mitchell et al., Nature Medicine 2021; DOI 10.1038/s41591-021-01336-3). Results have not translated into FDA approval: the agency issued a Complete Response Letter on 2024-08-09, functional unblinding and therapist-misconduct concerns were central to the decision, and three related MDMA papers were retracted in 2024 (the Nature Medicine paper was not).
Are psychedelics addictive?
Classical psychedelics (psilocybin, LSD, DMT, mescaline) are not considered chemically addictive. A review applying the Controlled Substances Act's eight factors concluded that medical psilocybin has low abuse potential (Johnson et al., Neuropharmacology 2018). They are not benign. They can amplify whatever you bring, which is why preparation and integration matter.
What is microdosing?
Taking amounts too small to produce a full psychedelic experience, usually on a repeating schedule. Reported benefits include improved mood and focus, but placebo-controlled studies (Szigeti et al., eLife 2021) suggest much of the effect is expectancy. Microdosing is not what Ceremonia practices; we work with full-dose ceremonial protocols. Microdosing evidence
What is set and setting?
Set is the participant's mindset: preparation, intention, current emotional state. Setting is the physical space, the music, the people present, and the relationship with facilitators. Clinical trials standardize preparation, the room and the therapist relationship, but no trial has isolated their individual effects.
How long do psychedelic effects last?
Acute effects: psilocybin 4 to 6 hours, ayahuasca 4 to 6 hours, LSD 8 to 12 hours, 5-MeO-DMT 10 to 30 minutes. In a randomized trial of 51 cancer patients, about 80% still showed clinically significant reductions in depressed mood and anxiety at the 6-month follow-up (Griffiths et al., J Psychopharmacol 2016). In an uncontrolled follow-up of 15 surviving patients from a separate NYU trial, about 60 to 80% still met response criteria at 4.5 years (Agin-Liebes et al., J Psychopharmacol 2020). These are research findings in people with life-threatening cancer, not outcomes of a retreat.
Are there people who shouldn't take psychedelics?
Yes. Personal or first-degree-relative history of psychosis, schizophrenia, or bipolar I is the strongest contraindication. SSRIs, SNRIs, MAOIs and lithium are contraindicated; anyone taking them completes a supervised taper with their prescriber before participating. Cardiac conditions and some other medical conditions require clearance. Ceremonia screens for all of these before accepting any participant; see /safety for the full protocol.
Reading science alongside your own questions
A study can help you ask better questions without deciding what a particular person should do. A laboratory experiment may investigate a receptor, a brain scan may describe a pattern of activity, and a clinical trial may measure symptoms over time. Those are different kinds of evidence. A finding in cells or animals cannot by itself tell us how a retreat participant will feel.
For example, when reading about psilocybin and depression, look for the people included, the comparison group, the support offered, and the length of follow-up. A trial of a screened clinical population with therapy does not establish the effects of a different setting. Bring questions about your health and medications to your own clinician; our preparation guide can help you organize them.
Begin
If you are weighing a next step.
The studies can inform your decision. They cannot make it for you. A readiness check is a good place to start, and you can book a connection call to ask your questions.